SAN DIEGO--(BUSINESS WIRE)--DTx Pharma, Inc. (DTx), a privately-held California biotechnology company developing novel RNA-based therapeutics to treat the genetic drivers of disease, today announced the appointment of Dr. Michael Huang as its Chief Medical Officer. Dr. Huang will provide leadership and supervision for DTx Pharma’s pipeline of clinical development programs.
“We are excited to welcome Dr. Huang to DTx Pharma at this pivotal time in our evolution. His caliber as a leader and deep experience in building effective teams for biotechnology companies will be invaluable as we continue to advance our pipeline,” said Arthur T. Suckow, Co-Founder and Chief Executive Officer of DTx Pharma.
With extensive leadership experience in advancing drug candidates through all phases of clinical development, his contributions have led to marketing authorizations for numerous therapeutics including Potiga®, Zevalin®, Uceris®, Ruconest®, and Austedo®.
Prior to DTx Pharma, Dr. Huang held key leadership roles at AmMax Bio and Spruce Biosciences. Through his career, he has led programs in RNA therapeutics, biologics and small molecules from initial IND through clinical proof-of-concept, late-stage development and beyond. Dr. Huang has also been recognized for supporting successful financing and business-development activities. He is also the author of a multitude of peer-reviewed journal articles, abstracts, and scientific publications.
Dr. Huang holds a Bachelor of Science in molecular and cell biology from the University of California at Berkeley and received his medical degree from the Chicago Medical School.
“What DTx Pharma has built is truly unique and incredibly valuable,” said Dr. Huang. “The team has created an impressive platform to help patients with genetic diseases. I’m both thrilled and grateful to join the team’s journey to ensure we can address countless disease targets currently undruggable due to disease-causing genes.”
About DTx Pharma
DTx Pharma, Inc. is a private clinical-stage biotechnology company tackling the challenges associated with treating genetic conditions by leveraging RNA-based therapeutics. The company’s proprietary delivery technology platform utilizes fatty acids as targeting ligands to enable the delivery of oligonucleotide therapies to tissues and cell types throughout the body. In preclinical studies, DTx has demonstrated cellular uptake and broad activity of oligonucleotides in the retina, muscle, heart, neurons, T cells, and other specialized cell types. To advance the FALCON platform toward and into clinical development, DTx has raised more than $100M in combined investment from several of the world’s leading healthcare investors including RA Capital Management and Access Biotechnology, pharmaceutical companies such as Eli Lilly and Company, the National Institute of Health (NIH), and research foundations such as the CMT Research Foundation (CMTRF). To learn more about DTx Pharma, please visit www.dtxpharma.com and follow DTx on LinkedIn and Twitter @DTxPharma.
